Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type 2 diabetes: a systematic review and meta-analysis of prospective cohort and before-after studies.

Chang G, Chen B, Zhang L

The Journal of dermatological treatment3 May 2021Cited by 33 (Europe PMC)

PMID33934692DOI10.1080/09546634.2021.1882658PepBankPUB-33934692

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanSystematic reviewEfficacy outcome
In patients with plaque psoriasis and type 2 diabetes, PASI scores were lower after GLP-1 receptor agonist treatment than before.
In plain wordsIn people with psoriasis and type 2 diabetes, psoriasis scores were lower after GLP-1 drug treatment than before it.
Peptide
Liraglutide
Outcome
DecreasePASI after versus before liraglutide
Study
n = 32
Comparator
Before treatment (same patients)
Outcome group
Skin and hair · Skin and wound
Studied dose
Dose not stated
Measurements
SMD
−4.332 NA
PASI, after vs before
Source sentences
Summary
Patients treated by GLP-1R after showed significantly lower PASI (SMD: -4.332, 95% CI: -7.611 to -1.053, p = .01)
1 context sentence(design, population, supporting numbers)
Summary · context
There were 4 trials involving 32 patients.
Report a problemFND-3393469201
02HumanSystematic reviewEfficacy outcome
In patients with plaque psoriasis and type 2 diabetes, fasting plasma glucose was lower after GLP-1 receptor agonist treatment than before.
In plain wordsIn people with psoriasis and type 2 diabetes, fasting blood sugar was lower after GLP-1 drug treatment than before it.
Peptide
Liraglutide
Outcome
DecreaseFasting plasma glucose after versus before liraglutide
Study
n = 32
Comparator
Before treatment (same patients)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
SMD
−0.341 NA
fasting plasma glucose, after vs before
Source sentences
Summary
lower fasting plasma glucose than treated before (SMD: -0.341, 95% CI: -0.679 to -0.004, p = .048).
1 context sentence(design, population, supporting numbers)
Summary · context
There were 4 trials involving 32 patients.
Report a problemFND-3393469202
03HumanSystematic reviewEfficacy outcome
In patients with plaque psoriasis and type 2 diabetes, BMI did not differ significantly after GLP-1 receptor agonist treatment compared with before.
In plain wordsIn people with psoriasis and type 2 diabetes, BMI did not change significantly after GLP-1 drug treatment compared with before it.
Peptide
Liraglutide
Outcome
No significant changeBMI after versus before liraglutide
Study
n = 32
Comparator
Before treatment (same patients)
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
There was no significant difference in Body Mass Index (BMI), Dermatology Life Quality Index (DLQI), and glycated hemoglobin (HbA1c) between treated by GLP-1R after and before.
1 context sentence(design, population, supporting numbers)
Summary · context
There were 4 trials involving 32 patients.
Report a problemFND-3393469203
04HumanSystematic reviewEfficacy outcome
In patients with plaque psoriasis and type 2 diabetes, the Dermatology Life Quality Index did not differ significantly after GLP-1 receptor agonist treatment compared with before.
In plain wordsIn people with psoriasis and type 2 diabetes, skin-related quality of life did not change significantly after GLP-1 drug treatment compared with before it.
Peptide
Liraglutide
Outcome
No significant changeDLQI after versus before liraglutide
Study
n = 32
Comparator
Before treatment (same patients)
Outcome group
Skin and hair · Skin and wound
Studied dose
Dose not stated
Source sentences
Summary
There was no significant difference in Body Mass Index (BMI), Dermatology Life Quality Index (DLQI), and glycated hemoglobin (HbA1c) between treated by GLP-1R after and before.
1 context sentence(design, population, supporting numbers)
Summary · context
There were 4 trials involving 32 patients.
Report a problemFND-3393469204
05HumanSystematic reviewEfficacy outcome
In patients with plaque psoriasis and type 2 diabetes, HbA1c did not differ significantly after GLP-1 receptor agonist treatment compared with before.
In plain wordsIn people with psoriasis and type 2 diabetes, HbA1c did not change significantly after GLP-1 drug treatment compared with before it.
Peptide
Liraglutide
Outcome
No significant changeHbA1c after versus before liraglutide
Study
n = 32
Comparator
Before treatment (same patients)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
There was no significant difference in Body Mass Index (BMI), Dermatology Life Quality Index (DLQI), and glycated hemoglobin (HbA1c) between treated by GLP-1R after and before.
1 context sentence(design, population, supporting numbers)
Summary · context
There were 4 trials involving 32 patients.
Report a problemFND-3393469205

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.